The European Medicines Agency's Committee for Medicinal Products for Human Use granted a positive opinion for conditional approval for Cell Therapeutics Inc.'s (Nasdaq: CTIC) Pixuvri sending the stock price soaring 25 cent to $1.36.
Conditional Approval Granted To Cell Therapeutics' Pixuvri
February 17, 2012 at 11:06 AM EST
